Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
34 results
D1.02 - Prevalence of allergic respiratory disorders in urban V/s rural Indian population
D1.03 - Sustainable and gluten free bread: Are legumes a hidden risk for occupational IgE-mediated respiratory allergy?
D1.04 - Diagnostic approach for respiratory symptoms linked to microbial contamination in metalworking fluids
D1.05 - Bet v 6 as a Marker of Pollen Cross-Reactivity in Southern Europe: Insights from a Birch-Free Region
D1.07 - Profile of sensitization to inhalant allergens in Valencia: Analysis of 1.898 skin prick tests over one year
D1.09 - Dynamics of pollen allergy in Ukraine during the full-scale invasion shows demand for diagnostics increased with changed sensitization patterns seen
D1.10 - Tree pollen allergy profile in Ukraine assessed by large-scale molecular component analysis
D1.11 - Age and Gender Patterns in Fungal Allergen Sensitization: A Study from Central Ukraine
D1.13 - EHealth tools suitability and technologic innovation use in an Environmental Exposure Chamber
D1.14 - Molecular Allergy Profiling of Pollen Sensitization in Cluj-Napoca
D1.15 - Relationship between sensitization to peanuts and tree nuts in children with allergic diseases in a population of the Russian Federation
D1.12 - Optimal Conventional Diagnostic Approach for Wheat Allergy in Chinese Children
D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.354 - Questionnaire survey of new treatments for atopic dermatitis
D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download